Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 7/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 7/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | AXL | P30530 | 1/20 | 0.50 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.50 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL443517 | 0.78 | LMNA (0.43) | CYP19A1CYP3A4CYP1A2RAB9ANPC1 | |
| SCHEMBL7240451 | 0.76 | ATM (0.33) | CYP2A6 | |
| SCHEMBL5540279 | 0.75 | RAB9A (0.47) | CYP2A6CYP3A4ALDH1A1RAB9ANPC1 | |
| SCHEMBL17625930 | 0.74 | ATM (0.42) | CYP2A6 | |
| SCHEMBL29419014 | 0.70 | CYP2A6 (1.00) | CYP19A1CYP2A6CYP3A4ALDH1A1CYP1A2 | |
| SCHEMBL120088 | 0.70 | CYP2A6 (1.00) | CYP19A1CYP2A6CYP3A4ALDH1A1CYP1A2 | |
| SCHEMBL30473120 | 0.70 | CYP2A6 (1.00) | CYP19A1CYP2A6CYP3A4ALDH1A1CYP1A2 | |
| SCHEMBL1830802 | 0.69 | CYP1A2 (0.36) | CYP19A1ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL17626098 | 0.69 | KMO (0.51) | ALDH1A1RAB9ANPC1KDM4EHPGD | |
| SCHEMBL468087 | 0.69 | CYP19A1 (0.45) | CYP19A1RAB9ANPC1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110997663-A | Benzofuran ureas or carbamates and heteroaromatic analogs thereof for use in therapy | 欧洲分子生物学实验室 | 2020-04-10 | — | — | CN | claimed |
| EP-1441719-B1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-03-30 | — | — | EP | claimed |
| US-7803819-B2 | DPP IV inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2010-09-28 | — | — | US | claimed |
| CN-1713907-B | N-substituted pyrrolidine derivatives as dipeptidyl peptidase IV inhibitors | HOFFMANN LA ROCHE | 2010-05-26 | — | — | CN | claimed |
| US-7470701-B2 | Substituted 2,5-heterocyclic derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-12-30 | — | — | US | claimed |
| US-20080255120-A1 | SUBSTITUTED 2,5-HETEROCYCLIC DERIVATIVES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-10-16 | — | — | US | claimed |
| US-20070259925-A1 | DPP IV INHIBITORS | BOEHRINGER MARKUS | 2007-11-08 | — | — | US | claimed |
| CN-1989131-A | Substituted thiophene derivatives as anti-cancer agents | CHIRON CORP (US) | 2007-06-27 | — | — | CN | claimed |
| EP-1732919-A1 | SUBSTITUTED THIOPHENE DERIVATIVES AS ANTI-CANCER AGENTS | CHIRON CORPORATION (US) | 2006-12-20 | — | — | EP | claimed |
| CN-1829721-A | Spiro '1-azabicyclo' 2.2.2! octan-3,5'-oxazolidin - 2'-one! derivatives with affinity to the alpha7 nicotinic acetylcholine receptor | ASTRAZENECA AB (SE) | 2006-09-06 | — | — | CN | claimed |
| US-20050096348-A1 | DPP IV inhibitors | BOEHRINGER MARKUS (CH) | 2005-05-05 | — | — | US | claimed |
| EP-1441719-A1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-04 | — | — | EP | claimed |
| US-20040116418-A1 | Compounds and methods for inhibition of HIV and related viruses | MEDIVIR AB (SE) | 2004-06-17 | — | — | US | claimed |
| US-20030130281-A1 | DPP IV inhibitors | HOFFMAN-LA ROCHE INC. | 2003-07-10 | — | — | US | claimed |
| WO-2003037327-A1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | F. HOFFMANN-LA-ROCHE AG (CH) | 2003-05-08 | — | — | WO | claimed |
| US-20020132794-A1 | Compounds and methods for inhibition of HIV and related viruses | MEDIVIR AB | 2002-09-19 | — | — | US | claimed |
| EP-0706514-B1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1998-11-18 | — | — | EP | claimed |
| JP-H09502702-A | — | — | 1997-03-18 | — | — | JP | claimed |
| EP-0706514-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1996-04-17 | — | — | EP | claimed |
| WO-1995006034-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1995-03-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255120-A1 | SUBSTITUTED 2,5-HETEROCYCLIC DERIVATIVES | CYP3A5, ABCG2, ABCB1 | CYP19A1 128/4885CYP2A6 44/4885CYP3A4 14/4885 |
| US-20070259925-A1 | DPP IV INHIBITORS | DPP4, DPP3, DPP7 | CYP19A1 887/4885CYP2A6 382/4885CYP3A4 82/4885 |
| US-20020132794-A1 | Compounds and methods for inhibition of HIV and related viruses | POLRMT, POLM, POLR1E | CYP19A1 2848/4885CYP2A6 2465/4885CYP3A4 916/4885 |
| US-20030130281-A1 | DPP IV inhibitors | DPP4, DPP3, DPP7 | CYP19A1 1019/4885CYP2A6 724/4885CYP3A4 171/4885 |
| US-20050096348-A1 | DPP IV inhibitors | DPP4, DPP3, DPP7 | CYP19A1 887/4885CYP2A6 382/4885CYP3A4 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.